Down-regulated FSTL5 promotes cell proliferation and survival by affecting Wnt/β-catenin signaling in hepatocellular carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 3, 2015, Pages 3386-3394

  Zhang, Dengyong ^a   Ma, Xiang ^a   Sun, Wanliang ^a   Cui, Peiyuan ^a   Lu, Zheng ^a  

^a BENGBU MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Cell proliferation; Follistatin like 5; Hepatocellular carcinoma; Wnt catenin signaling

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN, HUMAN; FOLLISTATIN RELATED PROTEIN; FSTL5 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; CANCER STAGING; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEP-G2 CELL LINE; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; TIME FACTOR; TUMOR VOLUME; WNT SIGNALING PATHWAY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; APOPTOSIS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; FEMALE; FOLLISTATIN-RELATED PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 84933033822     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24.
3. El-Serag HB and Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
4. Farazi PA and DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687.
5. Yang JD, Nakamura I and Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011; 21: 35-43.
6. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S and Lowe SW. An oncogenomics- based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008; 135: 852-864.
7. Masuda T, Kai N, Sakuma C, Kobayashi K, Koga H and Yaginuma H. Laser capture microdissection and cDNA array analysis for identification of mouse KIAA/FLJ genes differentially expressed in the embryonic dorsal spinal cord. Brain Res 2009; 1249: 61-67.
8. Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H and Ryzhova M. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 2011; 29: 3852-61.
9. Masuda T, Sakuma C, Nagaoka A, Yamagishi T, Ueda S, Nagase T and Yaginuma H. Follistatin-like 5 is expressed in restricted areas of the adult mouse brain: Implications for its function in the olfactory system. Congenit Anom (Kyoto) 2014; 54: 63-66.
10. Zhang P, Zhang P, Shi B, Zhou M, Jiang H, Zhang H, Pan X, Gao H, Sun H and Li Z. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis 2014; 5: e991.
11. Patel K, Connolly D, Amthor H, Nose K and Cooke J. Cloning and early dorsal axial expression of Flik, a chick follistatin-related gene: evidence for involvement in dorsalization/neural induction. Dev Biol 1996; 178: 327-342.
12. Towers P, Patel K, Withington S, Isaac A and Cooke J. Flik, a Chick Follistatin-Related Gene, Functions in Gastrular Dorsalisation/Neural Induction and in Subsequent Maintenance of Midline Sonic Hedgehog Signalling. Dev Biol 1999; 214: 298-317.
13. Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, Benner A, Ryzhova M, Sturm D and Witt H. FSTL5 improves prognostic subclassification of medulloblastoma. Cancer Res 2011; 71: 3447-3447.
14. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469-480.
15. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A and Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998; 95: 8847-8851.
16. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T and Nakamura Y. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998; 58: 2524-2527.
17. Lu P, Weaver VM and Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012; 196: 395-406.
18. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
19. Jones PA and Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
20. Fabbri M and Calin GA. Epigenetics and miRNAs in human cancer. Adv Genet 2010; 70: 87-99.